‘Immediately stop using': Chainsaws, pole saws recalled over laceration hazard
Published Thursday, the recall notice identifies four models of chainsaws and pole saws sold under the brand names Yardworks and Worx. According to Health Canada, affected units include main switches that may fail to operate properly, allowing the saws to 'continue to run even after the switch is released.'
A saw with a failed main switch poses a 'laceration hazard,' the recall says.
Affected WORX saws feature serial numbers with the first six digits ranging from 202408 to 202501, and include the following models:
Worx Electric Chainsaw, 8 Amp, 14-inch, model number and SKU WG305, in black and orange with 'WORX' marked on the body and bar of the saw.
Worx Electric Pole Saw, 8 Amp, 10-inch, model number and SKU WG309, in black and orange with 'WORX' marked on the body and bar of the saw, shipped with an eight-foot pole extension.
Affected Yardworks saws feature the serial numbers 1 47 24 or 2 43 24, and include the following models:
Yardworks 2-in-1 Electric Pole Saw, 9 Amp, 10-inch, model number 0545757, SKU 054-5757-2, in black and yellow-green with 'Yardworks' marked on the saw body and bar.
Yardworks Electric Corded Chainsaw, 9 Amp, 14-inch, model number 0545763, SKU 054-5763-6, in black and yellow-green with 'Yardworks' marked on the saw body and bar.
Health Canada notes that SKUs and serial numbers can be found on the product label.
Products under the recall were sold in Canada between September 2024 and March 2025, with just over 3,000 sold in that time. A further 49,000 affected units were sold in the United States.
The company reports that as of June 30, they have received no reports of incidents or injury related to the recalled products in Canada or the United States.
What to do with a recalled product
Health Canada is advising customers to 'immediately stop using' the recalled product, and to reach out to the manufacturer for directions on how to replace the saws.
Those in possession of recalled chainsaws and pole saws can contact Positec Canada by phone at 1-888-997-8871, via email at chainsawrecall@positecgroup.com or on the company's website.
Consumers are also reminded that selling or even giving away recalled items is prohibited, and that any incidents or injuries related to this or any product should be reported through Health Canada's online form.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
3 hours ago
- CTV News
CTV National News: P.E.I. strawberry growers battle devastating plant disease
Watch CTV's Maria Sarrouh reports on a serious disease threatening P.E.I.'s strawberry crops, affecting everything from root to fruit.
Cision Canada
6 hours ago
- Cision Canada
Public Advisory - NRA-Amlodipine 5 mg tablets: One lot recalled as some bottles may contain the wrong drug Français
Summary Product: NRA-Amlodipine 5 mg, DIN 02476460 Issue: Health products - Product safety What to do: Check your bottle of NRA-Amlodipine 5 mg tablets. The correct tablets are white or off-white and octagonal. If your bottle contains any round tablets, which are not the correct shape, or if you're unsure, return the bottle to your pharmacy for a replacement. If you are unable to get a replacement immediately, continue to take your medication as directed, but do not take the round tablets as these are the wrong medication. Contact your health care professional if you are dizzy, have unusually low blood pressure or slow heartbeats. If you are unable to access a health care professional and you are experiencing these symptoms, call 911. Affected products Issue Nora Pharma is recalling one lot of NRA-Amlodipine 5 mg tablets because some bottles may contain the wrong tablets, which have been identified as metoprolol succinate prolonged–release 12.5 mg tablets. NRA-Amlodipine treats high blood pressure and chest pain in adults and children aged 6 to 17. The tablets are white or off-white, octagonal, flat, and scored in the middle with '210' and '5' on one side. The metoprolol succinate prolonged-release 12.5 mg tablets are white, round and scored in the middle. While metoprolol is also used to treat high blood pressure and chest pain, substituting amlodipine (5 mg) with metoprolol (12.5 mg) can lead to serious side effects such as dangerous blood pressure changes (especially dangerously low drops), difficulty breathing, or an abnormally slow heart rate. Patients with other conditions (especially heart failure, asthma, severe peripheral arterial disease, pheochromocytoma, or diabetes) and those taking other medications could experience different side effects with varying levels of severity. Children taking the wrong medication may face a higher risk of serious side effects and potential harm. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to stop this issue from reoccurring. The Department will inform the public if any new health risks are identified. What you should do Check your medication bottle to ensure it only contains NRA-AMLODIPINE 5 mg tablets. If your bottle contains any round tablets, which are not the correct shape, or if you're unsure, return the bottle to your pharmacy for a replacement. If you are unable to get a replacement immediately, continue to take your medication as directed, but do not take the round tablets as these are the wrong medication. Contact your health care professional if you are dizzy, have unusually low blood pressure or slow heartbeats. If you are unable to access a health care professional and you are experiencing these symptoms, call 911. If you have questions about this recall, contact Nora Pharma Inc. by calling their Quality Assurance Department at 450-904-2355 or by emailing [email protected]. Report any health product-related side effects or complaints to Health Canada. Additional information for health professionals: Health care professionals, such as pharmacists, should check packages and bottles labelled NRA-AMLODIPINE 5 mg (amlodipine besylate) before dispensing to make sure they do not contain Metoprolol Succinate prolonged-release 12.5 mg tablets. Report any unusual bottles or other issues to the company and Health Canada.
CBC
10 hours ago
- CBC
'It's a pretty scary time': Oyster industry on edge after dermo found in Egmont Bay
The president of the P.E.I. Shellfish Association says the oyster industry is rightfully concerned about the first case of dermo disease in P.E.I. But Bob MacLeod said there is no reason for panic. "It's a pretty scary time for our industry right now," MacLeod said Saturday. The Canadian Food Inspection Agency announced on Friday that lab tests confirmed the presence of dermo — a highly damaging mollusc disease — in oysters from P.E.I.'s Egmont Bay. As a result, the CFIA could take control of how oysters are handled and shipped in that area to help limit the spread of the disease. MacLeod said that areas closing down will make fishers have to move to other rivers, which can cost them more money. "It affects every other fisherman on the Island because everyone's got to make a living, so everyone's gotta move around," he said. "It either affects that you gotta share … your river or it affects your cost because you have to travel further." There were approximately 600-700 licensed oyster fishers on P.E.I. as of October 2024, and many more wild oyster fishers, including MacLeod. "Even if it's a river that I don't fish in, somebody fishes in it." Moving forward The discovery of dermo in Island oysters comes one year after MSX, short for multinucleate sphere unknown, was discovered in Bedeque Bay. More cases were confirmed elsewhere in the province in the months that followed. "It's really challenging, hard on the head, very stressful and a lot of people's struggling over this," said MacLeod. He says the association's main objective is to enhance the industry, but that's difficult because of how limited they are in moving oysters from one area to another. He hopes the government will step up to support and compensate Island fishers. "Everyone's self-employed in this, and it's not the fault of the fishermen that these diseases [are] here," he said. With the right support, and some time, he thinks the industry can get past this hurdle. "We're talking a few years down the road to bring it back, but we can bring it back cause we have various [areas] not hit yet.
